New hope for diabetic nerve pain: experimental drug HRS-2129 enters human trials
NCT ID NCT07377721
First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 25 times
Summary
This study tests a new drug called HRS-2129 to see if it can safely reduce nerve pain caused by diabetes. About 168 adults with diabetic nerve pain will receive either HRS-2129, a placebo (dummy pill), or an approved pain drug (pregabalin) for comparison. The main goal is to measure how much pain scores drop after 4 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC PERIPHERAL NEUROPATHIC PAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, 400016, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.